Rehmann Capital Advisory Group’s DexCom DXCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $351K | Buy |
5,213
+359
| +7% | +$23.9K | 0.02% | 521 |
|
|
2026
Q1 | $305K | Buy |
4,854
+1,174
| +32% | +$81.8K | 0.02% | 547 |
|
|
2025
Q4 | $245K | Buy |
+3,680
| New | +$238K | 0.01% | 578 |
|
|
2025
Q3 | – | Sell |
-2,437
| Closed | -$213K | – | 646 |
|
|
2025
Q2 | $213K | Buy |
+2,437
| New | +$191K | 0.01% | 569 |
|
|
2024
Q3 | – | Sell |
-2,388
| Closed | -$271K | – | 597 |
|
|
2024
Q2 | $271K | Buy |
2,388
+7
| +0.3% | +$885 | 0.02% | 478 |
|
|
2024
Q1 | $330K | Sell |
2,381
-99
| -4% | -$12.4K | 0.02% | 426 |
|
|
2023
Q4 | $308K | Sell |
2,480
-76
| -3% | -$7.76K | 0.03% | 426 |
|
|
2023
Q3 | $238K | Sell |
2,556
-113
| -4% | -$12.7K | 0.02% | 453 |
|
|
2023
Q2 | $343K | Sell |
2,669
-556
| -17% | -$67.2K | 0.03% | 391 |
|
|
2023
Q1 | $375K | Sell |
3,225
-172
| -5% | -$19.3K | 0.04% | 364 |
|
|
2022
Q4 | $385K | Buy |
3,397
+64
| +2% | +$7.03K | 0.04% | 346 |
|
|
2022
Q3 | $268K | Buy |
3,333
+119
| +4% | +$10.1K | 0.03% | 410 |
|
|
2022
Q2 | $240K | Sell |
3,214
-222
| -6% | -$20.3K | 0.03% | 425 |
|
|
2022
Q1 | $439K | Buy |
3,436
+20
| +0.6% | +$2.19K | 0.04% | 331 |
|
|
2021
Q4 | $459K | Sell |
3,416
-244
| -7% | -$35.1K | 0.04% | 328 |
|
|
2021
Q3 | $500K | Sell |
3,660
-28
| -0.8% | -$3.53K | 0.05% | 316 |
|
|
2021
Q2 | $395K | Sell |
3,688
-3,092
| -46% | -$297K | 0.04% | 366 |
|
|
2021
Q1 | $346K | Buy |
6,780
+1,524
| +29% | +$143K | 0.04% | 374 |
|
|
2020
Q4 | $613K | Buy |
5,256
+1,668
| +46% | +$149K | 0.07% | 230 |
|
|
2020
Q3 | $370K | Sell |
3,588
-408
| -10% | -$42.6K | 0.05% | 288 |
|
|
2020
Q2 | $405K | Buy |
3,996
+4
| +0.1% | +$358 | 0.06% | 275 |
|
|
2020
Q1 | $269K | Buy |
+3,992
| New | +$248K | 0.04% | 308 |
|
|
2019
Q3 | – | Sell |
-5,304
| Closed | -$199K | – | 1762 |
|
|
2019
Q2 | $199K | Sell |
5,304
-552
| -9% | -$17.4K | 0.02% | 437 |
|
|
2019
Q1 | $174K | Sell |
5,856
-1,652
| -22% | -$58.1K | 0.02% | 439 |
|
|
2018
Q4 | $225K | Sell |
7,508
-1,532
| -17% | -$48.6K | 0.03% | 231 |
|
|
2018
Q3 | $323K | Sell |
9,040
-628
| -6% | -$19.5K | 0.04% | 287 |
|
|
2018
Q2 | $230K | Sell |
9,668
-732
| -7% | -$15.5K | 0.03% | 340 |
|
|
2018
Q1 | $193K | Buy |
+10,400
| New | +$154K | 0.03% | 381 |
|
Other funds holding DXCM
Rehmann Capital Advisory Group's DXCM Position: Q2 2026 in Review
Rehmann Capital Advisory Group increased its DexCom (DXCM) stake by 7.4% in Q2 2026, buying an estimated $23.9K and bringing the position to 5,213 shares worth $351K. The position accounts for 0.02% of the portfolio, ranked #521.
Rehmann Capital Advisory Group first reported a position in DXCM in Q1 2018 and has held it in 28 quarters since. The position peaked at $613K in Q4 2020. 974 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.
- Rehmann Capital Advisory Group held 5,213 shares of DexCom worth $351K as of Q2 2026.
- Rehmann Capital Advisory Group bought 359 DexCom shares in Q2 2026, an estimated $23.9K.
- DexCom made up 0.02% of Rehmann Capital Advisory Group's portfolio in Q2 2026, its #521 holding.
- Rehmann Capital Advisory Group first reported a position in DexCom in Q1 2018 and has held it in 28 quarters since.
- Rehmann Capital Advisory Group's DexCom position peaked at $613K in Q4 2020.
- 974 funds tracked by Wall St. Rank held DexCom as of Q2 2026.
Based on Rehmann Capital Advisory Group's 13F filing for Q2 2026, filed 20 Aug 2026.